V30-3

Medical use of cannabis for patients with end stage kidney disease
CLU: 2.0

V30-1

Hypoxia-inducible factor (HIF) stabilizers: An emerging treatment option for anemia in chronic kidney disease
CLU: 2.0

V29-4

Health Disparities and Outcomes in Canadian Indigenous End-Stage Kidney Disease Patients
CLU 2.0

V29-3

Potassium Binding Agents:  Patiromer and Sodium Zirconium Cycloscilicate
CLU 2.0

V29-2

Prevention and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease
CLU 2.0

V28-4

Prophylactic management of contrast-induced acute kidney injury in high-risk patients
CLU 2.0

V29-1

The role of Direct Oral Anticoagulant (DOACs) in Hemodialysis
CLU 2.0

V25-4

An introduction to chemotherapy-associated nephrotoxicity
CLU 3.0

V25-4

An introduction to chemotherapy-associated nephrotoxicity

V25-3

Warfarin for stroke prevention in hemodialysis patients with non-valvular atrial fibrillation

V28-2

Management of pain in patients on hemodialysis
CLU 2.0

V28-3

Restless Legs Syndrome (RLS) in hemodialysis patients
CLU 2.0

V28-1

Uremic pruritis
CLU 2.0

V27-4

Over-the-Counter Drugs to Avoid in Older Adults with Kidney Impairment
CLU 2.0

V27-3

Sodium glucose cotransporter 2 (SGLT2) inhibitors—Their role in the kidneys
CLU 2.0

V27-2

Antimicrobial stewardship: Is there a role in hemodialysis?
CLU 2.0

V27-1

Acute kidney injury secondary to lymphoma
CLU 2.0

V26-4

Drug dosing in dialysis
CLU 2.0

V26-3

Low molecular weight heparin for the treatment of deep vein thrombosis and pulmonary embolism in patients with chronic kidney disease
CLU 2.0